Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study
Background: Ameloblastoma is the most frequently encountered, enigmatic odontogenic tumor whose etiopathogenesis is still controversial. Understanding the pathogenic mechanism involved in Ameloblastoma and its proliferation aids in determining the best treatment option at an early stage. MAPK pathwa...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024002887 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553673055895552 |
|---|---|
| author | Aishwariya Mohanty Abikshyeet Panda Pallavi Mishra Lipsa Bhuyan Harish Kumar |
| author_facet | Aishwariya Mohanty Abikshyeet Panda Pallavi Mishra Lipsa Bhuyan Harish Kumar |
| author_sort | Aishwariya Mohanty |
| collection | DOAJ |
| description | Background: Ameloblastoma is the most frequently encountered, enigmatic odontogenic tumor whose etiopathogenesis is still controversial. Understanding the pathogenic mechanism involved in Ameloblastoma and its proliferation aids in determining the best treatment option at an early stage. MAPK pathway are known to be active during tooth development, and also mutations in MAPK components have been identified in both benign and malignant tumors. The aim of this study was to evaluate the Immunohistochemical expression of biomarker BRAF V600E and K-RAS in Ameloblastoma and to examine if any, correlation exists between BRAF V600E and K-RAS expression. Methods: 30 formalin-fixed paraffin-embedded blocks of histopathologically diagnosed cases of Ameloblastoma were taken as samples. Immunohistochemistry using K-RAS and BRAF V600E antibody was performed and slides were evaluated both quantitatively and qualitatively using a quick score by an independent observer. Results: K-RAS and BRAF V600E immunoexpression was evaluated and there is a significantly higher expression of K-RAS (mean score 6.20 ± 1.883) when compared with BRAF V600E (mean score 4.50 ± 2.271). BRAF V600E and K-RAS act independently in the pathogenesis of Ameloblastoma as the pattern of variation of BRAF V600E score was uneven when compared to K-RAS values. Conclusion: Our data provide evidence that two independent mutation occurs in the same molecular pathway driving Ameloblastomas. But there is no correlation between K-RAS and BRAF V600E expression. Hence, combination therapy of K-RAS and BRAF V600E inhibitors can be helpful for the treatment of Ameloblastoma. |
| format | Article |
| id | doaj-art-6d753d5b4ffc4dfb9fa128ead3c706a2 |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-6d753d5b4ffc4dfb9fa128ead3c706a22025-01-09T06:16:17ZengElsevierOral Oncology Reports2772-90602024-06-0110100442Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical studyAishwariya Mohanty0Abikshyeet Panda1Pallavi Mishra2Lipsa Bhuyan3Harish Kumar4Department of Oral & Maxillofacial Pathology and Oral Microbiology, S.C.B Dental College and Hospital, Cuttack, Odisha, IndiaDepartment of Oral & Maxillofacial Pathology and Oral Microbiology, Kalinga Institute of Dental Sciences, KIIT Deemed to Be University, Bhubaneswar, India; Corresponding author.Department of Oral & Maxillofacial Pathology and Oral Microbiology, Kalinga Institute of Dental Sciences, KIIT Deemed to Be University, Bhubaneswar, IndiaDepartment of Oral & Maxillofacial Pathology and Oral Microbiology, Kalinga Institute of Dental Sciences, KIIT Deemed to Be University, Bhubaneswar, IndiaDepartment of Oral & Maxillofacial Pathology and Oral Microbiology, Kalinga Institute of Dental Sciences, KIIT Deemed to Be University, Bhubaneswar, IndiaBackground: Ameloblastoma is the most frequently encountered, enigmatic odontogenic tumor whose etiopathogenesis is still controversial. Understanding the pathogenic mechanism involved in Ameloblastoma and its proliferation aids in determining the best treatment option at an early stage. MAPK pathway are known to be active during tooth development, and also mutations in MAPK components have been identified in both benign and malignant tumors. The aim of this study was to evaluate the Immunohistochemical expression of biomarker BRAF V600E and K-RAS in Ameloblastoma and to examine if any, correlation exists between BRAF V600E and K-RAS expression. Methods: 30 formalin-fixed paraffin-embedded blocks of histopathologically diagnosed cases of Ameloblastoma were taken as samples. Immunohistochemistry using K-RAS and BRAF V600E antibody was performed and slides were evaluated both quantitatively and qualitatively using a quick score by an independent observer. Results: K-RAS and BRAF V600E immunoexpression was evaluated and there is a significantly higher expression of K-RAS (mean score 6.20 ± 1.883) when compared with BRAF V600E (mean score 4.50 ± 2.271). BRAF V600E and K-RAS act independently in the pathogenesis of Ameloblastoma as the pattern of variation of BRAF V600E score was uneven when compared to K-RAS values. Conclusion: Our data provide evidence that two independent mutation occurs in the same molecular pathway driving Ameloblastomas. But there is no correlation between K-RAS and BRAF V600E expression. Hence, combination therapy of K-RAS and BRAF V600E inhibitors can be helpful for the treatment of Ameloblastoma.http://www.sciencedirect.com/science/article/pii/S2772906024002887AmeloblastomaK-RASBRAF V600EPathogenesisMAPK pathwayOdontogenic tumors |
| spellingShingle | Aishwariya Mohanty Abikshyeet Panda Pallavi Mishra Lipsa Bhuyan Harish Kumar Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study Oral Oncology Reports Ameloblastoma K-RAS BRAF V600E Pathogenesis MAPK pathway Odontogenic tumors |
| title | Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study |
| title_full | Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study |
| title_fullStr | Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study |
| title_full_unstemmed | Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study |
| title_short | Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study |
| title_sort | frequent mutation of k ras in addition to braf v600e in ameloblastoma an immunohistochemical study |
| topic | Ameloblastoma K-RAS BRAF V600E Pathogenesis MAPK pathway Odontogenic tumors |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024002887 |
| work_keys_str_mv | AT aishwariyamohanty frequentmutationofkrasinadditiontobrafv600einameloblastomaanimmunohistochemicalstudy AT abikshyeetpanda frequentmutationofkrasinadditiontobrafv600einameloblastomaanimmunohistochemicalstudy AT pallavimishra frequentmutationofkrasinadditiontobrafv600einameloblastomaanimmunohistochemicalstudy AT lipsabhuyan frequentmutationofkrasinadditiontobrafv600einameloblastomaanimmunohistochemicalstudy AT harishkumar frequentmutationofkrasinadditiontobrafv600einameloblastomaanimmunohistochemicalstudy |